April 2022 - CanadianCannabisWire

FridayApr 29, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands its Patent Portfolio With New Patent for Antiviral Drug Delivery with DehydraTECH

Lexaria just received another patent for DehydraTECH(TM): this time for the enhanced delivery of antiviral drugs This becomes the company’s 25th patent granted worldwide and the 10th granted in the U.S. It adds to the company’s growing patent portfolio, which also consists of ~50 pending patents worldwide Over the 2022 calendar year, the company seeks to also pursue regulatory and commercial advancement In 2016, Lexaria Bioscience (NASDAQ: LEXX) received its first United States patent grant and over the years, the company has been aggressive at broadening its patent suite, a move which it has attributed to refining the patent claims…

FridayApr 29, 2022 9:00 am

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Extends Michigan Expansion with Debut of Platinum Vape Live Resin; Announces Plans to Release Full-Year 2021 Results on May 2

Red White & Bloom and its wholly owned subsidiary RWB Michigan LLC recently announced the rollout of Platinum Vape(TM) Live Resin in Michigan The debut marks the company’s entry into the live resin in Michigan, which yield higher margins than the company’s existing distillate vape products RWB expects to release its full-year 2021 results on May 2, with the management hosting a conference call on May 3 Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator on a mission to become the most recognizable cannabis company in the United States, is celebrating the fulfillment of its…

WednesdayApr 27, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Fourth Human Study for Reducing Hypertension, Reports Positive Outcome of Third Human Study’s Data

Global drug delivery innovator Lexaria Bioscience is researching the ability of its patented DehydraTECH(TM) technology to improve the performance of a number of prescription drugs Lexaria is a world leader in the investigation of a DehydraTECH-processed cannabidiol (“CBD”) to potentially treat high blood pressure (hypertension), and study outcomes thus far have rendered positive results on effectiveness and patient tolerance The company is building a scorecard of data to support its planned FDA application for formal, registered clinical testing under the Investigational New Drug (“IND”) process Lexaria recently completed all data analyses of its HYPER-H21-3 study examining DehydraTECH-CBD’s ability to reduce…

MondayApr 25, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Advancing DehydraTECH-Nicotine Research to Support Safer, More Effective Oral Alternative to Harmful Pulmonary Administration Practices

Lexaria expects to begin dosing this summer as part of a human nicotine study, NIC-H22-1, to compare DehydraTECH-nicotine pouch performance to that of existing leading brands such as ON! and Zyn So far, the company’s animal studies have evidenced that the technology delivers outstanding results, including faster delivery, an increase in the quantity of peak nicotine delivered, higher brain levels of nicotine, and enhanced bioavailability In its most recent study, Lexaria established that DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls and peak levels achieved were up to 10x higher than controls Lexaria’s research aims to…

WednesdayApr 20, 2022 9:15 am

Flora Growth Corp. (NASDAQ: FLGC) Celebrates Finalization of Colombian Cannabis Export Protocols

Global cannabis brand Flora Growth Corp. is enjoying new opportunities for supplying its Colombian-grown high-THC and high-CBD flower to international markets, thanks to the finalization of regulatory framework allowing legal cannabis exports from the South American country Flora Growth is authorized to export non-psychoactive cannabidiol (“CBD”) products as well as up to 43,600 kg of products with high-tetrahydrocannabinol (“THC”) psychoactive cannabis content Flora Growth’s Cosechemos cultivation facility in central Colombia is currently capable of producing 600 kg of dried cannabis daily, as well as over 10,000 kg of cannabis derivatives annually under EU-GMP guidelines During the past 10 years, the…

MondayApr 18, 2022 9:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Advances its Human Nicotine Study and Announces New Nicotine Formulation Creation and Evaluation Program with Altria

Lexaria’s patented DehydraTECH(TM) technology has proven, in the NIC-A21-1 animal study, to be 10-20 times faster in reaching peak delivery of nicotine to the bloodstream than controls The company hopes to affirm this in the NIC-H22-1 human nicotine study as their DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States such as ON! and Zyn Lexaria has separately announced new agreements with Altria that will see the company receive a fee to provide certain DehydraTECH powder-based nicotine formulations that Altria will evaluate The company hopes that this, coupled with the human clinical study,…

TuesdayApr 12, 2022 9:15 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Gaining Advantage on Processing Rare Cannabinoids with the Help of Subsidiary Bay Medica

There is an urgent need for large-scale biosynthetic processing that preserves the purity and consistency of cannabinoids Acquired by InMed in October 2021, Bay Medica is a private U.S. firm specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector InMed has two cannabinol formulations currently in development for ocular and dermatological diseases – INM-088 (ocular for glaucoma) and INM-755 (dermatological cream for epidermolysis bullosa) The global cannabis market increased exponentially after the pandemic hit, and is anticipated to continue its upward trend over the next few years. The market was valued at $20.47 billion…

TuesdayApr 12, 2022 9:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX): A Review of Its Research Developments

Lexaria Bioscience, the global innovator behind DehydraTECH drug delivery technology, has continuously focused on research into its patented technology The company has conducted both in vitro testing and in vivo animal and human testing to evaluate the ability of DehydraTECH to improve the delivery of various APIs (active pharmaceutical ingredients) Lexaria has multiple other studies lined up aimed at building sufficient data to effect meaningful industry and/or regulatory progress and sustainable increases in valuation As it moves toward national and international implementation and commercialization of its patented DehydraTECH(TM) drug delivery technology, Lexaria Bioscience (NASDAQ: LEXX) is aware of the need…

WednesdayApr 06, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Multiple Strong Market Paths

Lexaria is a global innovator that has developed the patented DehydraTECH(TM) technology that improves bioavailability, speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”) The company strategically partners with third-party organizations seeking to explore formulation opportunities with their specific APIs Lexaria is evaluating the effectiveness of various DehydraTECH-processed APIs, including CBD, nicotine, sildenafil, and more According to company CEO Chris Bunka, the management team is positioning the company to ensure that it has multiple paths to success In pursuit of multiple paths to success, Lexaria Bioscience (NASDAQ: LEXX), developer of the patented DehydraTECH(TM) drug delivery platform, strategically partners…

WednesdayApr 06, 2022 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Increasing Rare Cannabidiol Product Portfolio, Revenues

InMed Pharmaceuticals is a Canadian clinical-stage drug development company focused on the development of rare cannabinoids and their synthetic counterpoints for B2B sales and pharmaceutical potential InMed expects to have rare cannabinoids CBDV and THCV available for B2B sale to the health and wellness market in the coming months, following on the heels of its CBC and CBT products The company recently reported its first revenues from CBC sales in the wake of its acquisition of rare cannabinoids manufacturer BayMedica late last year The company is also working to develop synthetic CBN cannabinoids as potential medical treatments for select conditions,…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 905.674.5977

Month: April 2022